Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase.
Catherine MarkSumit GuptaAngela PunnettJulia UptonJulia OrkinAdelle AtkinsonLindsay ClarkeAlice HeiseyChristine McGovernSarah AlexanderPublished in: Pediatric blood & cancer (2021)
Vaccinationis a critical tool in the prevention of COVID-19 infection for individuals and for communities. The mRNA vaccines contain polyethylene glycol (PEG) as a stabilizer. Currently, in North America, only the BNT162b2 (Pfizer-BioNTech) mRNA vaccine is approved for individuals aged 12-17. Most patients treated with contemporary regimens for acute lymphoblastic leukemia receive PEG-asparaginase (PEG-ASNase) and 10%-30% will develop allergic reactions. Optimizing access and safety for vaccine administration for these patients is critical. This report describes a process developed to support COVID vaccination in a cohort of adolescents and young adults with a history of PEG-ASNase allergy.
Keyphrases
- acute lymphoblastic leukemia
- drug delivery
- coronavirus disease
- sars cov
- end stage renal disease
- ejection fraction
- newly diagnosed
- allogeneic hematopoietic stem cell transplantation
- young adults
- chronic kidney disease
- binding protein
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- respiratory syndrome coronavirus